Letters, Statements & Analysis (2020)
Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and the patients we serve.
April
4/9/20
AMCP Submits Comment to FDA and FTC on Ensuring a Competitive Marketplace for Biosimilars
4/6/20
4/2/20
AMCP Signs on to ASAE Letter to Congress Regarding Association Economic Relief
March
3/27/20
AMCP Signs Coalition Letter to President on “Buy American” Requirements
3/26/20
AMCP Signs Pharmaceutical Supply Chain Stakeholder Letter
3/9/2020
AMCP Joins Stakeholder Letter on FDA Proposed Drug Importation Rule
3/6/2020
3/2/2020
AMCP Submits Comments on the CY 2021 Affordable Care Act Notice of Benefit and Payment Parameters
February
2/21/2020
AMCP Submits Comments on FDA Draft Guidance on the Drug Manufacturer Importation Pathway
2/5/2020
January
1/1/2020
AMCP Submits Comments to HHS OIG on Proposed Changes to the Federal Anti-Kickback Statute
